Abstract Number: 2768 • 2018 ACR/ARHP Annual Meeting
Comorbidity Accrual and Mortality in an Inception Cohort of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Single-Center, Observational Long-Term Study
Background/Purpose: Patients with giant-cell arteritis (GCA) and polymyalgia rheumatica (PMR) are treated with high cumulative glucocorticoid (GC) dose during their disease course. We sought to…Abstract Number: 2769 • 2018 ACR/ARHP Annual Meeting
A Single Center Experience of Temporal Artery Biopsies Performed in 30 African American Patients
Background/Purpose: Giant cell arteritis (GCA) is a systemic vasculitis of large and medium-sized arteries mostly reported in Caucasians (CCs) over 50 y.o. There is limited…Abstract Number: 2770 • 2018 ACR/ARHP Annual Meeting
The Effect of Metabolic Syndrome on Giant Cell Arteritis Treatment
Background/Purpose: The effects of metabolic syndrome on vasculature are complex, and studies exploring the role of metabolic syndrome (including diabetes mellitus, obesity, hypertension, and hyperlipidemia)…Abstract Number: 2771 • 2018 ACR/ARHP Annual Meeting
Current Practice of Cardiovascular Risk Assessment in Giant Cell Arteritis: A Single Center Study
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis affecting individuals over 50 years of age. Multiple epidemiological studies have determined increased risk of…Abstract Number: 2772 • 2018 ACR/ARHP Annual Meeting
Incidence of Cardiovascular Events in Giant Cell Arteritis: A Matched-Control Study
Background/Purpose: Cardiovascular risk in systemic vasculitis may be higher than in normal population, but there is scarce data. Ethnic component plays a role on certain…Abstract Number: 2773 • 2018 ACR/ARHP Annual Meeting
Diagnostic and Therapeutic Management of a Suspected Case of GCA: An Opinion Survey
Background/Purpose: Giant-cell arteritis (GCA) is the most common vasculitis. Specialists have formulated recommendations on how to manage a patient with a possible diagnosis of GCA.…Abstract Number: 2774 • 2018 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Ischemic Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Background/Purpose: Clinical trials have shown the efficacy of Methotrexate (MTX) in giant cell arteritis (GCA) but it is necessary to corroborate these results in real…Abstract Number: 2775 • 2018 ACR/ARHP Annual Meeting
Neutrophil to Lymphocyte Ratio Predicts Glucocorticoid Resistance in Polymyalgia Rheumatica
Background/Purpose: Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have been demonstrated to correlate with disease activity and predict treatment response in…Abstract Number: 2776 • 2018 ACR/ARHP Annual Meeting
Interleukin-6 Expression in Inflamed and Non-Inflamed Temporal Arteries from Patients with Giant Cell Arteritis
Background/Purpose: To evaluate if interleukin-6 (IL-6) expression in the temporal artery biopsy (TAB) specimens may differentiate patients with giant cell arteritis (GCA) from those without.…Abstract Number: 2777 • 2018 ACR/ARHP Annual Meeting
Dynamics in Peripheral Blood Cell Counts in Giant Cell Arteritis before Treatment, during Treatment and in Treatment-Free Remission
Background/Purpose: Giant cell arteritis (GCA) is an inflammatory disease of large vessels requiring long-term treatment with glucocorticoids. The immunopathology is characterized by vessel infiltrating innate…Abstract Number: 2778 • 2018 ACR/ARHP Annual Meeting
High Prevalence of Vascular Surgery and Autoimmune Comorbidity in Takayasu Arteritis
Background/Purpose: Large vessel vasculitis (LVV) is the arteritis in aorta and its major branches, and classified into Takayasu arteritis (TAK) and giant cell arteritis (GCA).…Abstract Number: 2779 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome and Prognostic Factors after Aortic Valve Surgery Due to Aortic Valve Regurgitation in Patients with Takayasu Arteritis
Background/Purpose: Aortic valve (AV) surgery is often performed for aortic regurgitation (AR) in patients with Takayasu arteritis (TA). However, data on the long-term outcomes, including…Abstract Number: 2780 • 2018 ACR/ARHP Annual Meeting
Insufficient Use of Corticosteroids Results in Higher Relapse in Takayasu Arteritis
Background/Purpose: Takayasu arteritis (TAK) is the chronic granulomatous inflammation of the aorta, its major branches. Although Corticosteroids, such as prednisolone (PSL), and immunosuppressants are key…Abstract Number: 2781 • 2018 ACR/ARHP Annual Meeting
Long Term Follow-up Results of Takayasu Arteritis Cohort: A Tertiary-Single Center Study
Background/Purpose: To assess the clinical characteristics and long term follow-up outcomes of patients with Takayasu’s arteritis (TAK) in a tertiary referral center. Methods: In this…Abstract Number: 2782 • 2018 ACR/ARHP Annual Meeting
Is It Necessary to Hold Anticoagulation Prior to Temporal Artery Biopsy?
Background/Purpose: Giant cell arteritis (GCA) and Temporal arteritis (TA) is characterized by chronic granulomatous inflammation in medium and large-sized vessels. It affects 20 in 100,000…
ACR Meeting Abstracts